TRVI
HealthcareTrevi Therapeutics, Inc.
$11.36
$-0.53 (-4.46%)
Jan 5, 2026
Price History (1Y)
Analysis
Trevi Therapeutics, Inc. is a biotechnology company within the healthcare sector. Its market capitalization stands at $1.46 billion, indicating a significant scale in the industry. The company has a relatively small workforce of 34 employees. Financially, Trevi Therapeutics has struggled to achieve profitability, with gross, operating, and profit margins all registering at 0.0%. This is reflected in its net income and EBITDA, which are negative $45.86 million and $51.20 million, respectively. The company's cash reserves of $194.93 million provide a cushion, but its debt of $823,000 and negative free cash flow of $28.82 million raise concerns about its financial health. Returns on equity and assets are also negative at -36.9% and -23.9%, respectively. The company's valuation metrics paint a mixed picture. The forward P/E ratio is -24.17, indicating significant losses in the near term. The price to book ratio stands at 7.68, suggesting that investors may be willing to pay a premium for Trevi Therapeutics' assets. However, the negative EV/EBITDA of -25.99 highlights the challenges the company faces in generating earnings.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Visit website →Key Statistics
- Market Cap
- $1.46B
- P/E Ratio
- N/A
- 52-Week High
- $14.39
- 52-Week Low
- $3.47
- Avg Volume
- 1.85M
- Beta
- 0.92
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 34